You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗股逆勢走強 國產疫苗全球接種超10億劑
格隆匯 06-07 13:22
格隆匯6月7日丨疫苗股逆勢走強 ,港股市場康希諾生物漲逾8%領漲;A股市場康希諾漲逾10%,瑞普生物漲5.47%。國家衞生健康委副主任曾益新表示,目前我國已有21個新冠病毒疫苗進入臨牀試驗階段。而且產能提升比預期的還要快,截止到6月5日,我們自己接種的大概有7個多億,出口的大概3.5個億。國內接種顯示,我國疫苗具有良好安全性,不良反應報吿發生率為11.86/10萬劑次。一般反應、異常反應發生率均低於2019年我國其他各類疫苗的平均報吿水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account